In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Orna Therapeutics, Inc.

https://www.ornatx.com/

Latest From Orna Therapeutics, Inc.

ReNAgade Emerges With $300m To Pursue Extra-Hepatic Delivery Of RNA Medicines

ReNAgade Therapeutics came out of stealth mode with $300m to fund its proprietary technology for delivery of RNA medicines – including coding, editing and gene insertion modalities – beyond the liver.

Financing Innovation

In Vivo’s Deals Of The Year: Cast Your Vote!

It is time for In Vivo's 15th annual Deals of the Year contest. We've selected 15 nominees across three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.

Deals Financing

RNA Medicines: Advancements Leading To Investments

Improvements in generating, purifying, and delivering RNA material, as well as addressing challenges with degradation by enzymes, have made the RNA class more attractive to drug developers.

Outlook 2023 Growth

AI/ML Grows In Importance, Holds Promise in mRNA

Industry experts at BioFuture 2022 highlighted the growing importance of digital technology in drug discovery and development, and also the limitations remaining.

Artificial Intelligence Vaccines
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
  • Biotechnology
    • Antisense, Oligonucleotides
UsernamePublicRestriction

Register